e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spyre Therapeutics, Inc. - Common Stock
(NQ:
SYRE
)
23.49
+1.02 (+4.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Spyre Therapeutics, Inc. - Common Stock
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
October 15, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
October 13, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
October 13, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
September 15, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
December 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.